Chemotherapy With or Without Additional Chemotherapy and/or Radiation Therapy in Treating Children With Newly Diagnosed Hodgkin's Disease
NCT00025259
Completed
This randomized phase III trial is studying different chemotherapy regimens given with or without radiation therapy to compare how well they work in treating children with newly diagnosed Hodgkin's disease. Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Giving the drugs in different combinations may kill more cancer cells. Radiation therapy uses high-energy x-rays to damage cancer cells. It is not yet known if chemotherapy is more ef... Read More
Gender:
ALL
Ages:
21 years and below
Trial Updated:
03/15/2017
Locations: University of Alabama at Birmingham Cancer Center, Birmingham, Alabama +174 locations
Conditions: Childhood Lymphocyte-Depleted Classical Hodgkin Lymphoma, Childhood Mixed Cellularity Classical Hodgkin Lymphoma, Childhood Nodular Lymphocyte Predominant Hodgkin Lymphoma, Childhood Nodular Sclerosis Classical Hodgkin Lymphoma, Stage I Childhood Hodgkin Lymphoma, Stage II Childhood Hodgkin Lymphoma, Stage III Childhood Hodgkin Lymphoma, Stage IV Childhood Hodgkin Lymphoma
Register for Updates
The Effects of Corticosteroids, Glucose Control, and Depth-of-Anesthesia on Perioperative Inflammation and Morbidity From Major Non-cardiac Surgery (Dexamethasone, Light Anesthesia and Tight Glucose Control (DeLiT Trial))
NCT00995501
Terminated
Evidence thus suggests that steroid administration, tight glucose control, and avoidance of deep anesthesia may decrease perioperative morbidity by reducing the inflammatory response to surgery. Using a three-way factorial approach, the investigators thus propose to test the primary hypotheses that major perioperative morbidity is reduced by: 1) low-dose dexamethasone; 2) intensive perioperative glucose control; and 3) lighter anesthesia. Secondary hypotheses include that each intervention redu... Read More
Gender:
ALL
Ages:
Between 40 years and 90 years
Trial Updated:
03/15/2017
Locations: Cleveland Clinic, Cleveland, Ohio
Conditions: Inflammation, Perioperative Morbidity
Register for Updates
A Study of DKN-01 and Lenalidomide/Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma
NCT01711671
Completed
A study to evaluate the safety, efficacy and bone changes with combination therapy of intravenous (IV) infused DKN-01 and lenalidomide/dexamethasone, versus lenalidomide and dexamethasone in relapsed or refractory multiple myeloma (MM) patients
Gender:
ALL
Ages:
30 years and above
Trial Updated:
03/08/2017
Locations: Emory University Hospital, Atlanta, Georgia +2 locations
Conditions: Multiple Myeloma
Register for Updates
Cortisol Suppression and Startle Responses in Posttraumatic Stress Disorder (PTSD)
NCT01477762
Completed
Posttraumatic stress disorder (PTSD) occurs in some people after exposure to events that cause extreme fear or helplessness. The incidence of war zones worldwide and the prevalence of violence in large cities in the U.S., increases the likelihood that people will experience a traumatizing event in their lifetime. About 1 in 10 people who survive such events will develop PTSD, while most people will get better over time. This suggests that some people may have biological vulnerabilities that make... Read More
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
03/07/2017
Locations: Grady Health System, Atlanta, Georgia
Conditions: Post Traumatic Stress Disorder
Register for Updates
A Pilot Study of Oncaspar® + Dexamethasone in Patients With Relapsed or Refractory T-Cell Lymphoma
NCT01878708
Terminated
This is an open-label, single-arm pilot study of Oncaspar® with dexamethasone for patients with relapsed or refractory peripheral T-cell lymphoma (PTCL), excluding extranodal NK/T cell lymphoma (ENKTL). Patients will receive up to 8 courses of treatment.
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
03/02/2017
Locations: Massachusetts General Hospital, Boston, Massachusetts +1 locations
Conditions: T-Cell Lymphoma, Relapsed T-Cell Lymphoma, Refractory T-Cell Lymphoma
Register for Updates
Phase II Study of "VIPER" Chemotherapy in Rel/Ref DLBCL
NCT00504751
Completed
Objectives The primary objective of this study is to: • determine the complete and partial response rates and the toxicity profile of bortezomib (VELCADE, formerly PS-341) when administered in combination with DICE chemotherapy plus rituximab (i.e. VIPER) to patients with relapsed or refractory diffuse large B-cell non-Hodgkin's lymphoma The secondary objectives of this study are to: * assess event free survival and overall survival * assess conversion of chemo-resistant to chemo-sensitive d... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/23/2017
Locations: Weill Cornell Medical College, New York, New York
Conditions: Non-Hodgkin's Lymphoma
Register for Updates
Analgesic Effect of IV Acetaminophen in Tonsillectomies
NCT01691690
Completed
Acetaminophen (paracetamol) is a first-line antipyretic and analgesic for mild and moderate pain for pediatric patients. Its common use (particularly in oral form) is underscored by its wide therapeutic window, safety profile, over the counter accessibility, lack of adverse systemic effects (as compared with NSAIDS and opioids) when given in appropriate doses. Although the exact anti-nociceptive mechanisms of acetaminophen continue to be elucidated, these mechanisms appear to be multi-factorial... Read More
Gender:
ALL
Ages:
Between 2 years and 9 years
Trial Updated:
02/21/2017
Locations: Nationwide Children's Hospital, Columbus, Ohio
Conditions: Adenotonsillitis, Tonsillitis
Register for Updates
Avastin, Fluorouracil, Doxorubicin and Streptozocin in Locally Advanced and Metastatic Pancreatic Endocrine Tumors
NCT00609765
Terminated
Open label, single-arm phase II study of avastin combined with fluorouracil, doxorubicin and streptozocin administered in 28-day cycles. Treatment will continue until progression of disease, or until withdrawal due to toxicity, or up to a maximum of 12 cycles (48 weeks). In order to reduce the risk of cardiac toxicity, doxorubicin will be administered for a maximum of 8 cycles. If disease has not progressed after 12 cycles of treatment, avastin monotherapy will continue until disease progression... Read More
Gender:
ALL
Ages:
Between 18 years and 80 years
Trial Updated:
02/20/2017
Locations: H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida
Conditions: Pancreatic Cancer
Register for Updates
A 3-Month Clinical Trial to Assess the Safety and Efficacy of the OZURDEX® Intraocular Implant in Patients With Diabetes Mellitus
NCT01673191
Completed
There is a need to find an effective therapy for diabetic patients who develop macular edema after cataract surgery.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/20/2017
Locations: Retinal Consultants of Arizona, Phoenix, Arizona
Conditions: Macular Edema, Diabetes Mellitus
Register for Updates
A Study of Thalidomide Plus Dexamethasone (Thal-Dex) Versus DOXIL plusThalidomide Plus Dexamethasone (DOXIL -Thal-Dex) in Patients With Newly Diagnosed Multiple Myeloma
NCT00097981
Completed
The purpose of this study is to determine if Thalidomide + Dexamethasone or DOXIL (doxorubicin HCl liposome injection) + Thalidomide + Dexamethasone is more effective in treating newly diagnosed patients with multiple myeloma. The number of patients whose multiple myeloma disappears for a period of time (complete Response) will be studied to make the determination of which treatment is more effective.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/20/2017
Locations: Not set, Fountain Valley, California +57 locations
Conditions: Multiple Myeloma
Register for Updates
Combination Chemotherapy and Radiation Therapy in Treating Patients With Acute Lymphoblastic Leukemia That Has Relapsed in the CNS or Testes
NCT00096135
Completed
RATIONALE: Drugs used in chemotherapy work in different ways to stop cancer cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage cancer cells. Giving combination chemotherapy together with radiation therapy may kill more cancer cells. PURPOSE: This clinical trial is studying how well giving chemotherapy together with radiation therapy works in treating patients with acute lymphoblastic leukemia that has relapsed in the CNS and/or testes.
Gender:
ALL
Ages:
Between 18 months and 29 years
Trial Updated:
02/14/2017
Locations: UAB Comprehensive Cancer Center, Birmingham, Alabama +152 locations
Conditions: Leukemia
Register for Updates
A Open-label Study of Ultra-High Dose Dexamethasone for Relapsed Multiple Myeloma
NCT02402725
Withdrawn
This is a phase II, open label, single-center study of ultra-high dose dexamethasone administered intravenously and orally as monotherapy for the treatment of relapsed multiple myeloma. Dexamethasone has known anti-myeloma activity, and has been studied extensively both alone, and in combination with other agents, in the treatment of multiple myeloma. This study implements an optimal 2-stage design. In Stage 1, 10 patients will be enrolled. Each patient will receive 100mg of intravenous dexamet... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/14/2017
Locations: Boston Medical Center, Boston, Massachusetts
Conditions: Multiple Myeloma
Register for Updates